Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Location
One Main Street, Suite 1350, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.45K % -32.3%
Debt-to-equity 4.99 % -4.58%
Return On Equity -36.6 % -28.9%
Return On Assets -34.8 % -29.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.1M shares +1.89%
Common Stock, Shares, Outstanding 59.1M shares +2.08%
Entity Public Float 1B USD +167%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 58.3M shares +36.5%
Weighted Average Number of Shares Outstanding, Diluted 58.3M shares +36.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 178M USD +31.7%
General and Administrative Expense 56.2M USD +17.8%
Operating Income (Loss) -235M USD -27.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -212%
Income Tax Expense (Benefit) -14.1M USD -134%
Net Income (Loss) Attributable to Parent -207M USD -45.4%
Earnings Per Share, Basic -2 USD/shares +24.9%
Earnings Per Share, Diluted -2 USD/shares +23.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 72.8M USD -36.7%
Cash, Cash Equivalents, and Short-term Investments 266M USD
Other Assets, Current 3.9M USD
Assets, Current 276M USD -59.3%
Other Long-term Investments 15.5M USD -49.5%
Property, Plant and Equipment, Net 569K USD -31.9%
Operating Lease, Right-of-Use Asset 1.18M USD -44.4%
Other Assets, Noncurrent 367K USD -20.2%
Assets 520M USD -23.6%
Accounts Payable, Current 2.46M USD +58.3%
Accrued Liabilities, Current 24.2M USD +16.9%
Liabilities, Current 28.1M USD +19.5%
Operating Lease, Liability, Noncurrent 125K USD -91.8%
Liabilities 28.2M USD +12.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 607K USD
Retained Earnings (Accumulated Deficit) -487M USD -73.8%
Stockholders' Equity Attributable to Parent 492M USD -25%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 492M USD -25%
Liabilities and Equity 520M USD -23.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2M USD -12.8%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 36.8M USD +184%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 59.1M shares +2.08%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 131M USD +49.9%
Deferred Tax Assets, Gross 132M USD +49%
Operating Lease, Liability 1.52M USD -44.4%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -206M USD -45.9%
Lessee, Operating Lease, Liability, to be Paid 1.6M USD -47.3%
Property, Plant and Equipment, Gross 1.34M USD 0%
Operating Lease, Liability, Current 1.39M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 872K USD -40.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 872K USD -40.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 85K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 32.1M USD +123%
Preferred Stock, Shares Issued 648K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 648K shares 0%
Depreciation, Depletion and Amortization 76K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 604K USD -33.9%
Share-based Payment Arrangement, Expense 38.3M USD +12.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%